Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 7/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.37 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8961801 | 0.73 | ALDH1A1 (0.38) | TSHRMAPK1ALDH1A1 | |
| SCHEMBL8211611 | 0.73 | CHRM1 (0.38) | CHRM1CHRM3CHRM5CHRM2CHRM4 | |
| SCHEMBL28761585 | 0.69 | SCN1A (0.42) | CHRM1CHRM3CHRM5CHRM2CHRM4 | |
| SCHEMBL15536281 | 0.65 | MEN1 (0.34) | — | |
| SCHEMBL24292362 | 0.65 | SCN1A (0.39) | CHRM1CHRM3CHRM5CHRM2CHRM4 | |
| SCHEMBL28965480 | 0.65 | SCN1A (0.39) | CHRM1CHRM3CHRM5CHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL28469489 | 0.64 | CYP3A4 (0.46) | CHRM1CHRM3CHRM5CHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL28126462 | 0.64 | CHRM5 (0.40) | CHRM1CHRM3CHRM5CHRM2CHRM4 | |
| SCHEMBL3780770 | 0.64 | CHRM1 (0.58) | CHRM1CHRM3CHRM5CHRM2CHRM4 | |
| Water SCHEMBL12506247 | 0.62 | CHRM1 (0.56) | CHRM1CHRM3CHRM5CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11007199-B2 | Compositions and methods for ameliorating pain and reducing fever | THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200230087-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING PAIN AND REDUCING FEVER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-07-23 | — | — | US | disclosed |
| WO-2012107532-A1 | 4-AMINOALCOHOLQUINOLINE DERIVATIVES, ENANTIOSELECTIVE SYNTHESIS METHODS AND THE USE THEREOF | Université de Picardie Jules Verne (FR) | 2012-08-16 | — | — | WO | disclosed |
| CN-1214790-C | Medicinal composition for treating inflammation | SEARLE & CO (US) | 2005-08-17 | — | — | CN | disclosed |
| CN-1442139-A | Medicinal composition for treating inflammation | SEARLE & CO (US) | 2003-09-17 | — | — | CN | disclosed |
| CN-1107058-C | Substituted isoxazoles for the treatment of disorders | SEARLE & CO (US) | 2003-04-30 | — | — | CN | disclosed |
| US-20020115657-A1 | Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma | JEPPESEN LONE (DK) | 2002-08-22 | — | — | US | disclosed |
| US-5849773-A | Amino acyl amino propargyl diol compounds for treatment of hypertension | G. D. SEARLE & CO. (US) | 1998-12-15 | — | — | US | disclosed |
| CN-1181075-A | Substituted isoxazoles for the treatment of disorders | SEARLE & CO (US) | 1998-05-06 | — | — | CN | disclosed |
| US-5411950-A | Benzo-fused oxazocinyl terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension | G. D. SEARLE & CO. (US) | 1995-05-02 | — | — | US | disclosed |
| US-4282246-A | Antidiabetic furancarboxylic and thiphenecarboxylic acids | PFIZER INC. (US) | 1981-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115657-A1 | Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma | PPARG, PPARA, PPARD | CHRM1 1192/4885CHRM3 1894/4885CHRM5 3241/4885 |
| US-20200230087-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING PAIN AND REDUCING FEVER | MPO, ACHE, CAT | CHRM1 4364/4885CHRM3 2036/4885CHRM5 2909/4885 |
| US-11007199-B2 | Compositions and methods for ameliorating pain and reducing fever | MPO, ACHE, CAT | CHRM1 4364/4885CHRM3 2036/4885CHRM5 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.